CHA
RNXT icon

Carmichael Hill & Associates’s RenovoRx RNXT Stock Holding History

Carmichael Hill & Associates’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$1K – 828
2021
Q4 		$1K Buy
+200
New +$1.19K ﹤0.01% 789

Other funds holding RNXT

LBC
Lawrence B. Cohen $2.06M AUM 34.47% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Carmichael Hill & Associates's RNXT Position: Q1 2022 in Review

Carmichael Hill & Associates sold out of RenovoRx (RNXT) in Q1 2022, closing a stake of 200 shares — an estimated $1K sold.

Carmichael Hill & Associates first reported a position in RNXT in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 12 funds tracked by Wall St. Rank hold RNXT as of Q1 2022.

  • Carmichael Hill & Associates reported no remaining RenovoRx position as of Q1 2022 after selling out during the quarter.
  • Carmichael Hill & Associates sold 200 RenovoRx shares in Q1 2022, an estimated $1K.
  • Carmichael Hill & Associates first reported a position in RenovoRx in Q4 2021 and held it in 1 quarter.
  • Carmichael Hill & Associates's RenovoRx position peaked at $1K in Q4 2021.
  • 12 funds tracked by Wall St. Rank held RenovoRx as of Q1 2022.

Based on Carmichael Hill & Associates's 13F filing for Q1 2022, filed 16 May 2022.